Ubs Asset Management Americas Inc Intellia Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 241,282 shares of NTLA stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

241,282

Previous 637,861 62.17%

Holding current value

$2.1 Million

Previous $5.98 Million 30.37%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$9.88 - $17.76 $3.92 Million - $7.04 Million	-396,579 Reduced 62.17%	241,282 $4.17 Million
Q2 2025 Aug 14, 2025	BUY	$6.28 - $9.67 $729,453 - $1.12 Million	116,155 Added 22.26%	637,861 $5.98 Million
Q1 2025 May 19, 2025	BUY	$7.11 - $12.8 $273,884 - $493,068	38,521 Added 7.97%	521,706 $3.71 Million
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $264,403 - $488,718	23,173 Added 5.04%	483,185 $5.63 Million
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $1.03 Million - $1.43 Million	-52,297 Reduced 10.21%	460,012 $9.45 Million

Q2 2024 Aug 13, 2024	BUY	$20.02 - $27.22 $2.66 Million - $3.61 Million	132,671 Added 34.95%	512,309 $11.5 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $1.25 Million - $1.72 Million	-52,374 Reduced 12.12%	379,638 $10.4 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $570,361 - $796,437	24,627 Added 6.05%	432,012 $13.2 Million
Q3 2023 Nov 13, 2023	SELL	$31.62 - $45.78 $358,570 - $519,145	-11,340 Reduced 2.71%	407,385 $12.9 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $848,517 - $1.14 Million	25,481 Added 6.48%	418,725 $15.6 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $326,487 - $616,305	-9,831 Reduced 2.44%	393,244 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $1.71 Million - $2.27 Million	31,670 Added 8.53%	403,075 $22.6 Million
Q2 2022 Aug 12, 2022	BUY	$38.49 - $76.21 $2 Million - $3.96 Million	52,001 Added 16.28%	371,405 $19.2 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $1.8 Million - $3.67 Million	30,815 Added 10.68%	319,404 $23.2 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $73,252 - $100,587	-727 Reduced 0.25%	288,589 $34.1 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $2.09 Million - $2.8 Million	15,824 Added 5.79%	289,316 $38.8 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $2.58 Million - $6.85 Million	42,301 Added 18.3%	273,492 $44.3 Million
Q1 2021 May 14, 2021	SELL	$46.59 - $83.68 $2.32 Million - $4.17 Million	-49,808 Reduced 17.73%	231,191 $18.6 Million
Q4 2020 Mar 01, 2021	BUY	$18.83 - $63.53 $4.07 Million - $13.7 Million	215,922 Added 331.79%	280,999 $15.3 Million
Q3 2020 Nov 13, 2020	BUY	$17.47 - $24.93 $89,725 - $128,040	5,136 Added 8.57%	65,077 $1.29 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $124,188 - $254,954	11,148 Added 22.85%	59,941 $1.26 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $72,216 - $119,187	7,650 Added 18.59%	48,793 $596,000
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $18,242 - $30,904	-1,749 Reduced 4.08%	41,143 $603,000
Q3 2019 Nov 14, 2019	BUY	$13.07 - $18.51 $322,005 - $456,030	24,637 Added 134.96%	42,892 $572,000
Q2 2019 Aug 15, 2019	BUY	$13.88 - $18.41 $253,379 - $336,074	18,255 New	18,255 $0
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $98,352 - $234,267	-8,635 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$25.78 - $32.6 $222,610 - $281,501	8,635 New	8,635 $0

Others Institutions Holding NTLA

# of Institutions

343

Shares Held

103M

Call Options Held

3.16M

Put Options Held

1.56M

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $661M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Intellia Therapeutics, Inc. Transaction History